Galena Biopharma Inc (GALE) Receives "Outperform" Rating from Oppenheimer
's stock had its "outperform" rating restated by equities research analysts at Oppenheimer in a research report issued to clients and investors on Friday, MarketBeat reports. They currently have a $4.00 price objective on the biotechnology company's stock.
from Biotech News
0 Comments